Buxton E J, Meanwell C A, Hilton C, Mould J J, Spooner D, Chetiyawardana A, Latief T, Paterson M, Redman C W, Luesley D M
West Midlands Cancer Research Campaign Clinical Trials Unit, Birmingham, England.
J Natl Cancer Inst. 1989 Mar 1;81(5):359-61. doi: 10.1093/jnci/81.5.359.
We report a phase II study of bleomycin, ifosfamide, and cisplatin (BIP) in cervical cancer. Our aims were to assess response rate, toxicity, and survival in women treated with this combination. Among 49 patients, 34 objective responses (69%) were seen, with 10 complete responses (20%). Toxic effects were assessed in 186 treatment cycles. All patients had alopecia and nausea and vomiting. Other effects included myelosuppression, infection, reduction in renal function, and disturbance of consciousness. These data indicate that BIP is highly active against advanced and recurrent cervical cancer.
我们报告了一项关于博来霉素、异环磷酰胺和顺铂（BIP）联合治疗宫颈癌的II期研究。我们的目的是评估接受该联合治疗的女性患者的缓解率、毒性和生存率。49例患者中，观察到34例客观缓解（69%），其中10例完全缓解（20%）。在186个治疗周期中评估了毒性作用。所有患者均出现脱发、恶心和呕吐。其他影响包括骨髓抑制、感染、肾功能减退和意识障碍。这些数据表明，BIP对晚期和复发性宫颈癌具有高度活性。
